Theranostic Drug Delivery Reinvented: Cyclotron and Nanotechnology Synergy

Department of Pharmacology, Clinical Pharmacology, SAMC&PGI, Sri Aurobindo University, Indore, Madhya Pradesh, India

*Corresponding author: Dr. Mohammad Nadeem Khan, Department of Pharmacology, Clinical Pharmacology, SAMC&PGI, Sri Aurobindo University, Indore, Madhya Pradesh-453555, India, Phone: 9303362451, E-mail: [email protected]

Received Date: March 11, 2025

Published Date: May 14, 2025

Citation: Khan MN, et al. (2025). Theranostic Drug Delivery Reinvented: Cyclotron and Nanotechnology Synergy. Mathews J Pharma Sci. 9(2):50.

Copyrights: Khan MN, et al. © (2025).

ABSTRACT

Cyclotron-driven theranostics is revolutionizing precision medicine by integrating advanced radionuclide production with nanotechnology-based drug delivery. Emerging radionuclides such as copper-64 (⁶⁴Cu), zirconium-89 (⁸⁹Zr), scandium-44 (⁴⁴Sc), and terbium-161 (¹⁶¹Tb) demonstrate superior diagnostic and therapeutic potential, offering multimodal imaging and targeted therapy capabilities. Functionalized nanocarriers enhance biodistribution, stability, and specificity, improving the therapeutic index of radiopharmaceuticals. Despite challenges in isotope availability, regulatory compliance, and large-scale manufacturing, advancements in hybrid nanocarriers, AI-driven drug design, and next-generation cyclotron technology are addressing these limitations. This review explores innovative approaches to enhance the clinical translation of theranostic isotopes, paving the way for personalized and highly effective precision medicine applications.

Keywords: Cyclotron-Driven Theranostics, Precision Medicine, Multimodal Imaging, Targeted Therapy, AI-Driven Drug Design, Radiopharmaceuticals, Hybrid Nanotechnology, Isotope Production.